CLDX Celldex Therapeutics
- 38.100
- +0.430+1.14%
- 38.190
- +0.090+0.24%
Celldex Therapeutics News
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study
Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in a phase 2 subcutaneous study of barzolvolimab in prurigo nodularis, a chronic skin disease that causes hard, intense
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo
We're Interested To See How Celldex Therapeutics (NASDAQ:CLDX) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Celldex Therapeutics: A Strong Buy on Impressive Barzolvolimab Results and Promising Pipeline
Celldex Therapeutics | 10-Q: Quarterly report
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000
04:05 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000
Celldex Therapeutics Q1 EPS $(0.56) Beats $(0.69) Estimate, Sales $156.00K Miss $920.00K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.69) by 18.84 percent. This is a 9.68 percent increase over losses of
Celldex Therapeutics: Cash, Cash Equivalents and Marketable Securities at March 31 Sufficient to Meet Estimated Working Cap Requirements and Fund Current Planned Ops Through 2027 >CLDX
Celldex Therapeutics: Cash, Cash Equivalents and Marketable Securities at March 31 Sufficient to Meet Estimated Working Cap Requirements and Fund Current Planned Ops Through 2027 >CLDX
Press Release: Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update - Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late br
Celldex Therapeutics 1Q Rev $156,000 >CLDX
Celldex Therapeutics 1Q Rev $156,000 >CLDX
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Health care stocks were mixed in Wednesday afternoon trading, with the NYSE Health Care Index fractionally higher and the Health Care Select Sector SPDR Fund (XLV) slightly lower. The iShares Biotechn
HC Wainwright & Co. : The Celldex Therapeutics (CLDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $80.00.
HC Wainwright & Co. : The Celldex Therapeutics (CLDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $80.00.
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics with a Buy and maintains $80 price target.
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients With Chronic Inducible Urticaria
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company's Phase 2 clinical study of barzolvolimab for the
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and maintains $67 price target.
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an "Inflammation &
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. ("Celldex" or the "Company") (NASDAQ:CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Shares of The Cooper Companies, Inc. (NYSE:COO) rose sharply during Friday's session after the company reported bette
Analysis
Price Target
No Data
